# Neoadjuvant Chemotherapy in Combination With Anlotinib and Benmelstobart for HR+/HER2- Breast Cancer (NEOTORCH-BREAST03)

> **NCT06874933** · PHASE2 · RECRUITING · sponsor: **First Affiliated Hospital of Zhejiang University** · enrollment: 35 (estimated)

## Conditions studied

- HR+/HER2- Breast Cancer

## Interventions

- **DRUG:** Neoadjuvant Chemotherapy in Combination with Anlotinib and Benmelstobart

## Key facts

- **NCT ID:** NCT06874933
- **Lead sponsor:** First Affiliated Hospital of Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-04
- **Primary completion:** 2027-04-01
- **Final completion:** 2030-04-01
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2025-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06874933

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06874933, "Neoadjuvant Chemotherapy in Combination With Anlotinib and Benmelstobart for HR+/HER2- Breast Cancer (NEOTORCH-BREAST03)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06874933. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*